What’s the Latest on MEDICARE DRUG PRICE Negotiations?

Posted on September 10, 2021 by Dr. David Edward Marcinko MBA MEd CMP™

BY KFF

Prescription drug costs are a major concern for consumers and a fiscal challenge for public and private payers, representing 10% of national health spending and nearly 20% of health benefit costs for large employers and Medicare.

In response, lawmakers are considering a broad range of policy options, including one that would allow the federal government to negotiate prescription drug prices on behalf of Medicare beneficiaries and people enrolled in private plans, a proposal that has strong bipartisan public support.

CITE: https://www.r2library.com/Resource/Title/0826102549

****

Could Negotiating Medicare Drug Prices Save $300 Billion Per Year? | Committee for a Responsible Federal Budget

This brief describes the current status of drug price negotiation proposals, looks back at the history of proposals to give the federal government the authority to negotiate drug prices in Medicare, describes the negotiation provisions in key legislation (H.R. 3), and discusses the potential spending effects for the federal government and individuals.

READ: https://www.kff.org/medicare/issue-brief/whats-the-latest-on-medicare-drug-price-negotiations/

UPDATE: https://www.msn.com/en-us/news/politics/medicare-trustees-sound-alarm-but-progressives-press-ahead-with-irresponsible-medicare-expansion/ar-AAOh6EA?li=BBnb7Kz

YOUR THOUGHTS AND COMMENTS ARE APPRECIATED.

Thank You

***

****

Filed under: Drugs and Pharma, Glossary Terms, Health Economics, Health Insurance, Health Law & Policy, Healthcare Finance | Tagged: , , | 1 Comment »